nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advancing data collection and analysis: 2023 revised European Network of Cancer Registries recommendations for standard dataset
|
Michalek, Irmina Maria |
|
|
199 |
C |
p. |
artikel |
2 |
A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305
|
Argiris, Athanassios |
|
|
199 |
C |
p. |
artikel |
3 |
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study
|
Mandalà, Mario |
|
|
199 |
C |
p. |
artikel |
4 |
Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium
|
Giorgi Rossi, Paolo |
|
|
199 |
C |
p. |
artikel |
5 |
Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
|
Pastorino, Alessandro |
|
|
199 |
C |
p. |
artikel |
6 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer: A long way to go
|
Zhao, Pengyue |
|
|
199 |
C |
p. |
artikel |
7 |
Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer
|
Osterman, Erik |
|
|
199 |
C |
p. |
artikel |
8 |
Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study
|
Catozzi, Simona |
|
|
199 |
C |
p. |
artikel |
9 |
Editorial Board
|
|
|
|
199 |
C |
p. |
artikel |
10 |
Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study
|
Roy, Soumyajit |
|
|
199 |
C |
p. |
artikel |
11 |
Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial
|
Li, Zeyang |
|
|
199 |
C |
p. |
artikel |
12 |
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
|
Taylor, Amelia M. |
|
|
199 |
C |
p. |
artikel |
13 |
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation
|
Cohen, Romain |
|
|
199 |
C |
p. |
artikel |
14 |
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
|
Blasi, Miriam |
|
|
199 |
C |
p. |
artikel |
15 |
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study
|
Carneiro, F. |
|
|
199 |
C |
p. |
artikel |
16 |
Incidence, clinical management and prognosis of patients with small intestinal adenocarcinomas from 1999 through 2019: A nationwide Dutch cohort study
|
de Back, Tim R. |
|
|
199 |
C |
p. |
artikel |
17 |
Letter re: Hyperprogression in advanced melanoma is not restricted to immunotherapy
|
Yang, Fan |
|
|
199 |
C |
p. |
artikel |
18 |
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
|
Tolaney, Sara M. |
|
|
199 |
C |
p. |
artikel |
19 |
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
|
Di Giacomo, Anna Maria |
|
|
199 |
C |
p. |
artikel |
20 |
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
|
Jacques, Sarah K. |
|
|
199 |
C |
p. |
artikel |
21 |
Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study
|
Yang, Zijian |
|
|
199 |
C |
p. |
artikel |
22 |
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives
|
ten Haaft, Britte H.E.A |
|
|
199 |
C |
p. |
artikel |
23 |
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
|
Brahmer, Julie R. |
|
|
199 |
C |
p. |
artikel |
24 |
Shrinking sample sizes in lung cancer trials: Various explanations, open questions
|
Olivier, Timothée |
|
|
199 |
C |
p. |
artikel |
25 |
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
|
Zhang, Panpan |
|
|
199 |
C |
p. |
artikel |
26 |
The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
|
Ertl, Carolin |
|
|
199 |
C |
p. |
artikel |
27 |
Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study
|
Van Der Sluis, Karen |
|
|
199 |
C |
p. |
artikel |